<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Lab Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann Lab Med</journal-id>
      <journal-id journal-id-type="publisher-id">ALM</journal-id>
      <journal-title-group>
        <journal-title>Annals of Laboratory Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2234-3806</issn>
      <issn pub-type="epub">2234-3814</issn>
      <publisher>
        <publisher-name>The Korean Society for Laboratory Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23667855</article-id>
      <article-id pub-id-type="pmc">3646203</article-id>
      <article-id pub-id-type="doi">10.3343/alm.2013.33.3.229</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
          <subj-group>
            <subject>Diagnostic Hematology</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Two Cases of Myeloproliferative Neoplasm with a Concurrent <italic>JAK2</italic><sup>V617F</sup> Mutation and <italic>BCR/ABL</italic> Translocation without Chronic Myelogenous Leukemia Phenotype Acquisition during Hydroxyurea Treatment</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Park</surname>
            <given-names>Sang Hyuk</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Chi</surname>
            <given-names>Hyun-Sook</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cho</surname>
            <given-names>Young-Uk</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jang</surname>
            <given-names>Seongsoo</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Park</surname>
            <given-names>Chan-Jeoung</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Dae-Young</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Je-Hwan</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Kyoo-Hyung</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Laboratory Medicine, University of Ulsan, College of Medicine and Asan Medical Center, Seoul, Korea.</aff>
      <aff id="A2"><label>2</label>Department of Internal Medicine, Division of Hematology, University of Ulsan, College of Medicine and Asan Medical Center, Seoul, Korea.</aff>
      <author-notes>
        <corresp>Corresponding author: Hyun-Sook Chi. Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, 86 Asanbyeongwon-gil, Songpa-gu, Seoul 138-736, Korea. Tel: +82-2-3010-4502, Fax: +82-2-478-0884, <email>hschi@amc.seoul.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>4</month>
        <year>2013</year>
      </pub-date>
      <volume>33</volume>
      <issue>3</issue>
      <fpage>229</fpage>
      <lpage>232</lpage>
      <history>
        <date date-type="received">
          <day>08</day>
          <month>11</month>
          <year>2012</year>
        </date>
        <date date-type="rev-recd">
          <day>11</day>
          <month>1</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>2</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Korean Society for Laboratory Medicine.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor</p>
    <p>Myeloproliferative neoplasms (MPNs) are categorized on the basis of <italic>BCR/ABL</italic> translocation occurrence as either Philadelphia-positive CML or Philadelphia-negative MPNs (Ph-MPNs). MPNs include polycythaemia vera (PV), essential thrombocythaemia (ET), and primary myelofibrosis (PMF) [<xref ref-type="bibr" rid="B1">1</xref>]. The <italic>JAK2</italic><sup>V617F</sup> mutation, which is specific for Ph-MPN, occurs in more than 95% PV cases and in approximately 50% ET and PMF cases [<xref ref-type="bibr" rid="B1">1</xref>]. The 2008 revision of the WHO classifies MPNs into 2 categories, <italic>BCR/ABL</italic> positive CML and Ph-MPNs, on the basis of the presence or absence of the Philadelphia chromosome [<xref ref-type="bibr" rid="B2">2</xref>].</p>
    <p>Although the 2008 WHO classification does not include MPNs with more than 1 genetic aberration as a distinct disease entity, some cases with coexistence of <italic>JAK2</italic><sup>V617F</sup> mutation and <italic>BCR/ABL</italic> translocation have been recently reported and up to 28 cases have been previously reported [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. Among these reports, the majority of the patients either had pre-existing <italic>BCR/ABL</italic>-positive CML and developed <italic>JAK2</italic><sup>V617F</sup> mutation while undergoing tyrosine kinase inhibitor treatment [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B7">7</xref>] or developed <italic>BCR/ABL</italic>-positive CML with a pre-existing <italic>JAK2</italic><sup>V617F</sup> mutation-positive MPN [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. In contrast, a small number of patients showed simultaneous occurrence of both <italic>JAK2</italic><sup>V617F</sup> mutation and <italic>BCR/ABL</italic> translocation, with a CML phenotype in the bone marrow (BM) with development of symptoms or morphology associated with <italic>JAK2</italic><sup>V617F</sup> mutation, and with MPN only after imatinib treatment [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>]. We report 2 MPN cases that were simultaneously positive for both <italic>JAK2</italic><sup>V617F</sup> mutation and <italic>BCR/ABL</italic> translocation and that did not acquire the CML phenotype during hydroxyurea (Korea United Pharm, Seoul, Korea) treatment.</p>
    <p>Case 1 was a 36-yr-old man who was admitted in November 2009 with severe thrombocytosis. The patient's hemogram results at admission were as follows: white blood cells, 9.4&#xD7;10<sup>9</sup>/L, Hb, 13.8 g/dL, and platelets, 830&#xD7;10<sup>9</sup>/L. The peripheral blood smear (PBS) and BM biopsy revealed a marked increase in the platelet and the clustered megakaryocyte numbers (9.2/high power field) without evidence of dysplasia. Allele-specific PCR for <italic>JAK2</italic><sup>V617F</sup> mutation detection and reverse-transcriptase PCR (RT-PCR) for <italic>BCR/ABL</italic> fusion transcript detection using custom-designed primers was performed. The PCR and the RT-PCR analyses showed that the patient was positive for <italic>JAK2</italic><sup>V617F</sup> heterozygous mutation and the <italic>BCR/ABL</italic> fusion transcript (b3a2 type), respectively.</p>
    <p>Subsequently, the <italic>JAK2</italic><sup>V617F</sup> mutation allele burden was quantified by real-time quantitative PCR using JAK2 Muta<italic>Quant</italic>&#x2122; (Ipsogen, Marseille, France). The <italic>JAK2</italic><sup>V617F</sup> mutation allele burden was calculated as the percentage of the V617F copy number to the sum of V617F and wild-type copy number. The <italic>JAK2</italic><sup>V617F</sup> mutation allele burden was quantified to be 27.91% (7,200/25,800) at diagnosis. The major <italic>BCR/ABL</italic> fusion transcripts quantitation was also performed by real-time PCR using the LightCycler t(9;22) Quantification kit (Roche Diagnostics, Mannheim, Germany) and the normalized copy number (NCN) was 0.02 at diagnosis. The patient's karyotype was determined to be 46,XY [<xref ref-type="bibr" rid="B20">20</xref>]; however, his interphase FISH analysis result was nuc ish(ABL1x3,BCRx2)(ABL1 con BCRx1)[61/200], representing cryptic <italic>BCR/ABL</italic> fusion on der(22)t(9;22) in 30.5% of the total cells.</p>
    <p>Thus, on the basis of these findings, the patient was diagnosed to have ET with a major <italic>BCR/ABL</italic> fusion transcript. The patient was treated with hydroxyurea and the initial response during the first year of treatment was promising (<italic>BCR/ABL</italic> fusion transcript maintained in the range of 0.005 NCN to 0.01 NCN). However, despite continuing treatment, the number of <italic>BCR/ABL</italic> fusion transcripts increased to 5.0 NCN in the second year of follow-up, which indicated treatment failure. Interestingly, the patient did not show morphological evidence of CML during the follow-up period.</p>
    <p>Case 2 was a 58-yr-old man diagnosed with leukocytosis and splenomegaly on admission. The patient's hemogram results at admission were as follows: white blood cells, 19.7&#xD7;10<sup>9</sup>/L, Hb, 13.0 g/dL, and platelets, 285&#xD7;10<sup>9</sup>/L. The PBS showed an occasional presence of tear-drop cells and immature granulocytes with blasts (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). The BM biopsy showed extensive myelofibrosis (grade 2-3) with a cellularity of 90% and an increased number of dysplastic megakaryocytes (<xref ref-type="fig" rid="F1">Fig. 1B</xref>). The myelofibrosis was demonstrated by the reticulin silver stain (<xref ref-type="fig" rid="F1">Fig. 1C</xref>). At diagnosis, the <italic>JAK2</italic><sup>V617F</sup> mutation analysis showed a heterozygous mutation (<xref ref-type="fig" rid="F1">Fig. 1D</xref>) and the <italic>JAK2</italic><sup>V617F</sup> mutation allele burden was quantified to be 69.66% (2,640/3,790). The RT-PCR analysis revealed the presence of <italic>BCR/ABL</italic> fusion transcript (b3a2 type) (<xref ref-type="fig" rid="F1">Fig. 1E</xref>). The patient's karyotype was determined to be 46,XY, t(9;22)(q34;q11.2)[4]/46,XY[16]. The quantification result for the major <italic>BCR/ABL</italic> fusion transcript in BM was found to be 1.0 NCN at diagnosis, which was 50-fold higher than that of case 1. The patient was treated with hydroxyurea for 6 months. However, the <italic>BCR/ABL</italic> fusion transcript levels remained at the levels at diagnosis (1.0-1.6 NCN). Similar to the findings for case 1, the morphological evidence of CML was not evident during hydroxyurea treatment. The drug treatment was changed to dasatinib and after 7 months of dasatinib treatment the patient did not show conversion, which was indicative of successful treatment.</p>
    <p>Of the previously reported 28 cases with both <italic>JAK2</italic><sup>V617F</sup> mutation and <italic>BCR/ABL</italic> translocation, 15 patients had <italic>BCR/ABL</italic>-positive CML and acquired a <italic>JAK2</italic><sup>V617F</sup>-positive MPN phenotype after tyrosine kinase inhibitor treatment. Although 4 out of the 15 patients were diagnosed with CML and were shown to possess <italic>JAK2</italic><sup>V617F</sup> mutation, 3 of the 4 patients did not show a morphology associated with <italic>JAK2</italic><sup>V617F</sup> mutation-positive MPN until after treatment with imatinib. In contrast, 9 of the 28 patients showed <italic>JAK2</italic><sup>V617F</sup> mutation-positive MPN phenotype at initial diagnosis and developed <italic>BCR/ABL</italic>-positive CML during hydroxyurea treatment. Finally, at initial diagnosis, 4 patients showed mixed phenotype associated with both <italic>BCR/ABL</italic>-positive CML and <italic>JAK2</italic><sup>V617F</sup> mutation-positive MPN [<xref ref-type="bibr" rid="B3">3</xref>].</p>
    <p>In recent studies, 2 hypotheses have been proposed to explain the coexistence of both <italic>BCR/ABL</italic> translocation and <italic>JAK2</italic><sup>V617F</sup> mutation in some patients. The first hypothesis which has been favored in the several literatures proposes that a single clone possesses one aberration and the patient's phenotype (e.g. CML feature) is dependent on the dominant clone (e.g. <italic>BCR/ABL</italic> translocation positive) which is determined by the selective pressure exerted by the specific treatment (e.g. hydoxyurea) prescribed for the other clone (e.g. <italic>JAK2</italic><sup>V617F</sup> mutation positive) [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. The second hypothesis proposes that a single clone concurrently possesses both the <italic>BCR/ABL</italic> translocation and <italic>JAK2</italic><sup>V617F</sup> mutation [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>]. This hypothesis was supported by a recent study, which reported that the <italic>BCR/ABL</italic> translocation occurred in a pre-existing <italic>JAK2</italic><sup>V617F</sup> mutation-positive clone [<xref ref-type="bibr" rid="B18">18</xref>]. The data obtained in this study supports the second hypothesis as shown by the detection of concurrent <italic>JAK2</italic><sup>V617F</sup> mutation and <italic>BCR/ABL</italic> translocation at the initial diagnosis of MPN, and the lack of phenotype switch, especially to the CML phenotype, during hydroxyurea treatment. Hence, a comprehensive molecular genetic analysis is needed to elucidate the pathogenesis of these hematological chimeras.</p>
    <p>In addition, the 2 patients showed different outcomes according to both the initial level of <italic>BCR/ABL</italic> fusion transcripts and the introduction of a tyrosine kinase inhibitor during the hydroxyurea treatment. The patient with low initial <italic>BCR/ABL</italic> fusion transcript levels experienced a relatively good initial response to hydroxyurea treatment, although the treatment failed 2 years later. In contrast, the patient with high <italic>BCR/ABL</italic> fusion transcript levels did not initially respond well to hydroxyurea treatment, but a dramatic response was achieved after a treatment change to dasatinib. On the basis of these findings, we speculate that treatment with a tyrosine kinase inhibitor can be effective and therefore recommend this approach in <italic>JAK2</italic><sup>V617F</sup>-positive MPN patients with a concurrent <italic>BCR/ABL</italic> translocation, particularly if the initial <italic>BCR/ABL</italic> fusion transcript level is high.</p>
    <p>In conclusion, we report 2 cases of MPN with concurrent <italic>JAK2</italic><sup>V617F</sup> mutation and <italic>BCR/ABL</italic> translocation without CML phenotype acquisition during the hydroxyurea treatment. Treatment with tyrosine kinase inhibitors can be effective, particularly if the initial <italic>BCR/ABL</italic> fusion transcript level is high in these patients. Further molecular genetic analysis is needed to elucidate the pathogenesis of these hematological chimeras.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>No potential conflicts of interest relevant to this article were reported.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tefferi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms</article-title>
          <source>Leukemia</source>
          <year>2008</year>
          <volume>22</volume>
          <fpage>14</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="pmid">17882280</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Swerdlow</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Campo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Pileri</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <source>WHO classification of tumours of haematopoietic and lymphoid tissues</source>
          <year>2008</year>
          <edition>4th ed</edition>
          <publisher-loc>Lyon</publisher-loc>
          <publisher-name>IARC Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hummel</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kletecka</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Sanks</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Chiselite</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Roulston</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>LB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms</article-title>
          <source>Diagn Mol Pathol</source>
          <year>2012</year>
          <volume>21</volume>
          <fpage>176</fpage>
          <lpage>183</lpage>
          <pub-id pub-id-type="pmid">22847163</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>V&#xE9;ron&#xE8;se</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tchirkov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Richard-Pebrel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ledoux-Pilon</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fleury</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chaleteix</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm</article-title>
          <source>Leuk Res</source>
          <year>2010</year>
          <volume>34</volume>
          <fpage>e94</fpage>
          <lpage>e96</lpage>
          <pub-id pub-id-type="pmid">19833389</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Inami</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Inokuchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Okabe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kosaka</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mitamura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia</article-title>
          <source>Leukemia</source>
          <year>2007</year>
          <volume>21</volume>
          <fpage>1103</fpage>
          <lpage>1104</lpage>
          <pub-id pub-id-type="pmid">17301812</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Campiotti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Appio</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Solbiati</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ageno</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Venco</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia</article-title>
          <source>Leuk Res</source>
          <year>2009</year>
          <volume>33</volume>
          <fpage>e212</fpage>
          <lpage>e213</lpage>
          <pub-id pub-id-type="pmid">19589593</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders</article-title>
          <source>Leuk Res</source>
          <year>2008</year>
          <volume>32</volume>
          <fpage>993</fpage>
          <lpage>995</lpage>
          <pub-id pub-id-type="pmid">18055011</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bee</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Gan</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Nadarajan</surname>
              <given-names>VS</given-names>
            </name>
            <name>
              <surname>Latiff</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Menaka</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders</article-title>
          <source>Int J Hematol</source>
          <year>2010</year>
          <volume>91</volume>
          <fpage>136</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="pmid">20047097</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bocchia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vannucchi</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Gozzetti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guglielmelli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Poli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Crupi</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Insights into JAK2-V617F mutation in CML</article-title>
          <source>Lancet Oncol</source>
          <year>2007</year>
          <volume>8</volume>
          <fpage>864</fpage>
          <lpage>866</lpage>
          <pub-id pub-id-type="pmid">17913657</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jallades</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hayette</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tigaud</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Coiffier</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Magaud</surname>
              <given-names>JP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis</article-title>
          <source>Leuk Res</source>
          <year>2008</year>
          <volume>32</volume>
          <fpage>1608</fpage>
          <lpage>1610</lpage>
          <pub-id pub-id-type="pmid">18448166</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scott</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Baxter</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Todd</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Edkins</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>106</volume>
          <fpage>2920</fpage>
          <lpage>2921</lpage>
          <pub-id pub-id-type="pmid">16204151</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mirza</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Frantz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Clarke</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Voth</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Transformation of polycythemia vera to chronic myelogenous leukemia</article-title>
          <source>Arch Pathol Lab Med</source>
          <year>2007</year>
          <volume>131</volume>
          <fpage>1719</fpage>
          <lpage>1724</lpage>
          <pub-id pub-id-type="pmid">17979493</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conchon</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Novaes</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Dorlhiac-Llacer</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>de Alencar Fischer Chamone</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bendit</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia</article-title>
          <source>Int J Hematol</source>
          <year>2008</year>
          <volume>88</volume>
          <fpage>243</fpage>
          <lpage>245</lpage>
          <pub-id pub-id-type="pmid">18626727</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mizutani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kuroda</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Horiike</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Taniwaki</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia</article-title>
          <source>Int J Hematol</source>
          <year>2010</year>
          <volume>91</volume>
          <fpage>516</fpage>
          <lpage>521</lpage>
          <pub-id pub-id-type="pmid">20146031</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>SF</given-names>
            </name>
          </person-group>
          <article-title>Coexistence of JAK2V617F mutation and BCR-ABL1 transcript in two Chinese patients with chronic myelogenous leukemia</article-title>
          <source>Acta Haematol</source>
          <year>2012</year>
          <volume>127</volume>
          <fpage>47</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="pmid">22025110</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hussein</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bock</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Seegers</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Flasshove</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Henneke</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Buesche</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation</article-title>
          <source>Blood</source>
          <year>2007</year>
          <volume>109</volume>
          <fpage>4106</fpage>
          <lpage>4107</lpage>
          <pub-id pub-id-type="pmid">17449802</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bornh&#xE4;user</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mohr</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Oelschlaegel</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Bornh&#xE4;user</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jacki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ehninger</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis</article-title>
          <source>Leukemia</source>
          <year>2007</year>
          <volume>21</volume>
          <fpage>1824</fpage>
          <lpage>1826</lpage>
          <pub-id pub-id-type="pmid">17476275</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kr&#xE4;mer</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>JAK2-V617F and BCR-ABL--double jeopardy?</article-title>
          <source>Leuk Res</source>
          <year>2008</year>
          <volume>32</volume>
          <fpage>1489</fpage>
          <lpage>1490</lpage>
          <pub-id pub-id-type="pmid">18439674</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cambier</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Renneville</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cazaentre</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Soenen</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Cossement</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Giraudier</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders</article-title>
          <source>Leukemia</source>
          <year>2008</year>
          <volume>22</volume>
          <fpage>1454</fpage>
          <lpage>1455</lpage>
          <pub-id pub-id-type="pmid">18288134</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gattenlohner</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>V&#xF6;lker</surname>
              <given-names>HU</given-names>
            </name>
            <name>
              <surname>Etschmann</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Einsele</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>M&#xFC;ller-Hermelink</surname>
              <given-names>HK</given-names>
            </name>
          </person-group>
          <article-title>BCR-ABL positive chronic myeloid leukemia with concurrent JAK2 (V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T)</article-title>
          <source>Am J Hematol</source>
          <year>2009</year>
          <volume>84</volume>
          <fpage>306</fpage>
          <lpage>307</lpage>
          <pub-id pub-id-type="pmid">18951468</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>The hematological and molecular characteristics of case 2. (A) A peripheral blood smear revealed tear-drop cells, immature granulocytes, and blasts (Wright stain, &#xD7;400). (B) The patient's bone marrow biopsy showed extensive myelofibrosis (H&amp;E stain, &#xD7;100), demonstrated by reticulin silver stain (C, &#xD7;100) with cellularity of 90% and increased dysplastic megakaryocytes. (D) Mutational analysis of <italic>JAK2</italic><sup>V617F</sup> revealed bands that corresponded to both the mutant and wild-type <italic>JAK2</italic> (sized 299 bp and 229 bp, respectively). (E) Along with the myeloproliferative neoplasms (MPNs) diagnosis tests, reverse transcriptase (RT)-PCR analysis of <italic>BCR/ABL</italic> fusion transcripts was performed and a single 305-bp band, representing the major <italic>BCR/ABL</italic> translocation (b3a2 type), was obtained.</p>
      </caption>
      <graphic xlink:href="alm-33-229-g001"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
